Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148202 | 0.93 | IDO1 (0.34) | MALT1IDO1SLC6A9F10NAMPT | |
| SCHEMBL592178 | 0.92 | MALT1 (0.40) | MALT1IDO1DRD4CCR8F10 | |
| SCHEMBL590218 | 0.91 | MALT1 (0.37) | MALT1IDO1DRD4CCR8F10 | |
| SCHEMBL1148325 | 0.91 | MALT1 (0.37) | MALT1IDO1CCR8F10NAMPT | |
| SCHEMBL1148147 | 0.90 | F10 (0.38) | MALT1IDO1SLC6A9F10NAMPT | |
| SCHEMBL1148161 | 0.90 | MALT1 (0.38) | MALT1DRD4 | |
| SCHEMBL1148185 | 0.89 | TSHR (0.37) | MALT1IDO1CCR8F10 | |
| SCHEMBL1148277 | 0.88 | MALT1 (0.35) | MALT1IDO1DRD4CCR8 | |
| SCHEMBL1148600 | 0.88 | MALT1 (0.36) | MALT1IDO1DRD4CCR8F10 | |
| SCHEMBL1148301 | 0.88 | MALT1 (0.35) | MALT1IDO1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264021-B1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264021-A1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | MALT1 3967/4885IDO1 288/4885DRD4 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.